Another phase II trial (NCT00524277) assessed the GP2 peptide vaccine efficacy in disease-free breast cancer patients (lymph node-positive/negative, HLA-A2 + , HER2/neu by Immunohistochemistry 1–3 +), in the subject to either presence or absence of 500 μg of GP2 with 125 μg of GM-CSF (Mittendorf et al. 2016). The gene discussed is CSF2; the disease is breast carcinoma.